Press Releases

Nov 03

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene therapy program demonstrates enhanced muscle tropism and microdystrophin expression - - Company ends Q3

Read More
Nov 02

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development Consortium is building a collaboration of patients, industry, regulators, academia, payers and other

Read More
Oct 21

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Co-Founder, President and Chief Executive Officer, and Carl

Read More
Oct 04

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development , Scale Up and cGMP Manufacturing Services CAMBRIDGE, Mass. & COLUMBUS, Ohio --(BUSINESS WIRE)--Oct. 4, 2021-- Solid Biosciences Inc. (Solid, Nasdaq: SLDB), a life sciences company focused on

Read More
Sep 29

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration - - Data presented at the Child Neurology Society 50 th Annual Meeting - CAMBRIDGE,

Read More
Sep 23

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) - - Patient reported outcomes showed sustained improvements at 1.5 years compared

Read More
Sep 20

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress - CAMBRIDGE, Mass. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.

Read More
Sep 20

Solid Biosciences to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , Ph.D., Chief Operating Officer, and Carl Morris , Ph.D.,

Read More
Aug 24

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass. , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful

Read More
Aug 19

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

CAMBRIDGE, Mass. , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President,

Read More
Aug 19

Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

CAMBRIDGE, Mass. , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar , CPA, MBA, has joined the Company as Senior Vice President,

Read More
Aug 16

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results

- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultragenyx collaboration, next generation gene therapy programs for Duchenne patients - - Company ends Q2 with

Read More
Jul 02

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

CAMBRIDGE, Mass. , July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President,

Read More
Jul 01

Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy

-Additional expertise expected to support attainment of key corporate goals- CAMBRIDGE, Mass. , July 01, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the

Read More
Jun 07

Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer

CAMBRIDGE, Mass. , June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer,

Read More
Jun 07

Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer

CAMBRIDGE, Mass. , June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer,

Read More
May 26

Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , PhD, Chief Operating Officer, will present at the Jefferies

Read More
May 25

Solid Biosciences to Present at Upcoming Scientific Conferences

CAMBRIDGE, Mass. , May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific

Read More
May 14

Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results

- Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event - - Long-term biopsy data generated from the ongoing IGNITE DMD trial demonstrate durable microdystrophin

Read More
May 11

Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021

CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before the market opens

Read More
May 04

Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting

-Data from studies of novel AAV vectors and AAV immunology and an encore of 12-month safety, efficacy and patient-reported outcomes measurements from the ongoing IGNITE DMD trial of SGT001 to be presented- CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.

Read More
Apr 20

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

CAMBRIDGE, Mass. , April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , Ph.D., Chief Operating Officer, and Louise Perry , Head of

Read More
Mar 25

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris , Ph.D., Chief Scientific Officer, will participate in a panel

Read More
Mar 23

Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of

Read More
Mar 18

Solid Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its

Read More
Mar 17

Solid Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. , (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares

Read More
Mar 15

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) - - Patient 7,

Read More
Mar 04

Solid Biosciences Reports Inducement Grant to New Chief Legal Officer

CAMBRIDGE, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Legal Officer,

Read More
Mar 04

Solid Biosciences Announces Appointments to Management Team and Board of Directors

-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),

Read More
Feb 24

Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference

- IGNITE DMD Principal Investigator, Dr. Barry Byrne , to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18 - -Company to host external key opinion leaders at a symposium to discuss Real World Outcomes Measures in Duchenne Muscular Dystrophy during the

Read More
Feb 17

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider , PhD, Chief Technology Officer, and Cathryn Clary , MD, MBA,

Read More
Jan 06

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Chief Executive Officer, President and Co-Founder, will present

Read More

News & Events

Press Releases